Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vascular Pharmaceuticals Inc.

www.vascularpharma.com

Latest From Vascular Pharmaceuticals Inc.

J&J Taking The Long View With Its Therapeutic Franchises

The Big Pharma has only recently entered the diabetes drug market, but has plans to make a significant impact on how the disease is treated. During a meeting with analysts, J&J highlighted the deals it’s made and the multiple indications it will pursue within the metabolic space.

BioPharmaceutical Strategy

Biopharma Dealmaking Quarterly Statistics, Q3 2012

Q3 2012 biopharma financing, at just over $3 billion, showed a 13% increase over Q2. Follow-on public offerings again were the most prevalent financing type, accounting for a third of these dollars. M&A volume was down to just over $7 billion, compared with Q2’s $35.9 billion and only two Q3 transactions topped the billion-dollar mark. Antibody alliances made up just over a quarter of the total $2.2 billion in deal volume, with 19 deals signed in the area.

BioPharmaceutical Deals

Start-Up Execs On The Move, October 2012

Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.

BioPharmaceutical Medical Device

Recent Financings Of Private Companies, October 2012

START-UP's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical equipment & supplies.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Vascular Pharmaceuticals Inc.
  • Senior Management
  • Richard Shea, CEO
    Bonnie Layman, CFO
    David Clemmons, MD, CSO
    Elizabeth Stoner, MD, Chief Dev. Officer
  • Contact Info
  • Vascular Pharmaceuticals Inc.
    Phone: (919) 345-7933
    510 Meadowmont Village Way, Ste. 283
    Chapel Hill, NC 27517
    USA
UsernamePublicRestriction

Register